Abstract
To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma. Forty-five chemotherapy-naive pts (28 male and 17 female) with a median age of 60 years (range 35–74) were enrolled. 5-FU 2 g/m2was given weekly over 24 h i.v. preceded by folinic acid 500 mg/m2as a 2 h infusion. Paclitaxel 175 mg/m2was administered as a 3 h-infusion on days 1 and 22 and cisplatin 50 mg/m2as 1 h infusion on days 8 and 29. Six weeks of therapy (days 1, 8, 15, 22, 29, 36) followed by 2 weeks rest were considered one cycle. A median of 3 cycles (range 1–4) were administered to 45 pts assessable for response, survival and toxicity. Five pts (11%) obtained a CR and 18 pts (40%) a PR (ORR 51%; 95% Cl: 35.8–66.3%). Responses were achieved in the liver, lymph nodes, lungs and at the site of the primary tumour. Nine pts (20%) had stable disease. Thirteen pts (29%) were considered to have failed treatment, 8 pts (18%) due to progressive disease and 5 pts (11%) who did not receive one complete cycle of therapy due to acute non-haematologic toxicity. The median progression-free and overall survival times were 9 months (range 1–36+) and 14 months (range 2–36+), respectively. Neutropenia WHO III°/IV° occurred in 7 pts (15%) with only 1 pt having grade IV. Additional non-haematologic WHO III°/IV° toxicities included nausea/vomiting in 5 (11%), alopecia in 22 (49%), and diarrhoea in 1 patient each (2%). Dose reductions or treatment delays were necessary in 8 pts (17%), mainly due to neutropenia. All pts were treated on an outpatient basis. The combination of paclitaxel, cisplatin and continuously infused 5-FU/folinic acid appears to be a highly active regimen for the treatment of pts with advanced gastric cancer. While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R and Mansfield PF (1998) Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269–274
Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S and Morrell L (1991) A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma [see comments]. J Clin Oncol 9: 625–630
Belani C, Luketich JD, Landreaneau RJ, Kim R, Ramanathan RK, Day R, Ferson PF, Keean RJ, Posner M, Seeger J and Lembersky B (1997) Efficacy of cisplatin, 5-flurouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol 24: 89–92
Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C and Kanz L (1997a) A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8: 396–399
Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L and Kanz L (1997b) Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 24: S19–S19
Cascinu S, Ficarelli R, Safi MA, Graziano F, Catalano G and Cellerino R (1997) A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 33: 1699–1702
Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET and Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9: 307–310
Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK and Chi CW (1996) Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77: 14–18
Findley M and Cunningham D (1993) Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 19: 29–44
Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H and Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163–168
Harstrick A, Vanhoefer U and Wilke H (1994) Interaction of taxol with cisplatin, etoposide and 5-FU in human gastric carcinoma cell lines. Proc Am Assoc Cancer Res 35: 332
Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Meyer F, Kanz L and Bokemeyer C (1999) Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anti-Cancer Drugs 10: 729–733
Ilson DH, Ajani JA, Bhalla K, Forastiere AA, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C and Kelsen DP (1998) Phase II trial of paclitaxel, fluororuacil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16: 1826–1834
Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y and Adachi KI (1996) Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704–710
Kaplan E and Meier P (1958) Nonparametric estimation from incomplete observations. Am J Stat Assoc 53: 457–481
Kelsen DP, Atiq OT and Saltz L (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541–548
Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT and Kim HJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813–3818
Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH and Kim JS (1999) Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85: 295–301
Klein HO, Wickramanayak PD and Farrkh GR (1986) 5-fluroruracil (5-FU), adriamycin (ADM) and methotrexate (MTX) – a combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc Am Soc Clin Oncol 84: 86
Miller AB, Hoodgstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–211
Murad AM (1999) Chemotherapy for advanced gastric cancer: Focus on new agents and combinations. Cancer Control 6: 361–368
Okada Y, Anai H, Hattori T, Maehara Y, Nishimura J, Sugimachi K and Nawata H (1991) Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer. Anticancer Drugs 2: 453–456
Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ and Buente H (1989) Phase II study with etoposide, doxorubicin, and cisplatin in advanced and measurable gastric cancer. J Clin Oncol 9: 1310–1317
Pyrhönen S, Kuitunen Z and Nyandoto P (1995) Randomized comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587–591
Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser Ph, Ychou M, Elias D, Cvitkovic E, Armand JP and Droz J-P (1994) Efficacy of combined 5-fluroruracil and cisplatin in advanced gastrc carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30A: 1263–1269
Rowinsky EK, Cazenave LA and Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247–1259
Scanlon KJ, Newman EM, Lu Y and Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923–8925
Schabel FM, Trader ML, Laster WR, Corbett TH and Griswold DP (1979) Cis-dichlorodiammine-platinum (II): combination chemotherapy and cross resistance studies with tumor of mice. Cancer Treat Rep 63: 1459–1473
Schipper DL and Wagener DJ (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7: 137–149
Vanhoefer U, Wilke H, Weh J, Clemens M, Harstrick A, Stahl M, Hossfeld DK and Seeber S (1994) Weekly high-dose 5-FU and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 5: 850–851
Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J and Seeber S (1995) Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A: 92–97
Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Jofe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M and Hicksih T (1999) Long-term survival fater epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80: 269–272
Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JH, Hughes M, Mansi J, Findley M, Hill A, Oates J, Nicolson M, Hicksih T, O'Brian M, Iveson T, Watson M, Underhill C, Wardley A and Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261–167
Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, Schober C, Link H, Meyer HJ and Lucke B (1990) High-dose folinic acid/etoposide/5-fluroruracil in advanced gastric cancer-a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8: 65–70
Wilke H, Wils J and Rougier P (1995) Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/5-FU in advanced gastric cancer (GC). Atrial of the EORTC Gastrointestinal Tract Cooperative Group and the AIO (Arbeitsgemeinschaft Internistische Onkologie). Proc Am Soc Clin Oncol 14: 206
Wilke H, Korn M, Vanhofer U, Fink U, Stahl M, Preusser P, Kohne C, Klassen U, Harstrick A, Schmoll HJ and Seeber S (1996a) Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother 6: 123–126
Wilke H, Korn M, Köhne C, Fink U, Preusser P, Vanhoefer U, Wiegmann T, Stahl M, Harstrick A, Klassen U, Schmoll HJ and Seeber S (1996b) Phase II results of weekly infusional high-dose FU (HD-FU) plus folinic caid (FA) and biweekly cisplatin (C) in advanced gastric cancer. Ann Oncol 7(suppl 5): 46
Wils J (1996) The treatment of advanced gastric cancer. Semin Oncol 23: 397–406
World Health Organization (1998) World Health Report 1998: A vision for all. World Health Organization: Geneva, Switzerland
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kollmannsberger, C., Quietzsch, D., Haag, C. et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83, 458–462 (2000). https://doi.org/10.1054/bjoc.2000.1295
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1295
Keywords
This article is cited by
-
Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma
World Journal of Surgical Oncology (2014)
-
Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients
International Journal of Clinical Oncology (2014)
-
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine
Medical Oncology (2012)
-
The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract
European Journal of Medical Research (2011)
-
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer
Gastric Cancer (2010)